60% Cholesterol Reduction: New Drug Trial Results
Oral Medication Enlicitide Shows Promise in Lowering ‘Bad’ Cholesterol In a significant advancement for cardiovascular health, a newly developed oral medication, enlicitide, has demonstrated a remarkable ability to reduce low-density lipoprotein (LDL) cholesterol – often referred to as “bad” cholesterol – by approximately 60% in a large-scale clinical trial. This level of efficacy is comparable … Read more